Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Straus

Showing results (161-170 of 215) with videos related to

Pageof 22
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 1993
Accelerated hyperfractionated total-lymphoid irradiation, high-dose chemotherapy, and autologous bone marrow transplantation for refractory and relapsing patients with Hodgkin's diseaseJ Yahalom, S C Gulati, M Toia, et al.
Cancer|December 1, 1981
Angioimmunoblastic lymphadenopathy: clinical spectrum of diseaseP K Schauer, D J Straus, C M Bagley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1990
A phase I toxicity, pharmacology, and dosimetry trial of monoclonal antibody OKB7 in patients with non-Hodgkin's lymphoma: effects of tumor burden and antigen expressionD A Scheinberg, D J Straus, S D Yeh, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 18, 2007
Maintaining the dose intensity of ICE chemotherapy with a thrombopoietic agent, PEG-rHuMGDF, may confer a survival advantage in relapsed and refractory aggressive non-Hodgkin lymphomaC H Moskowitz, P A Hamlin, J Gabrilove, et al.
Cell Reports|September 9, 2023
The heat shock protein Hsp27 controls mitochondrial function by modulating ceramide generationRowan A Boyd, Saurav Majumder, Johnny Stiban, et al.
Leukemia & Lymphoma|September 7, 2000
Granulocyte-colony stimulating factor (G-CSF) may improve disease outcome in elderly patients with diffuse large cell lymphoma (DLCL) treated with CHOP chemotherapyG B Donnelly, J Glassman, C Long, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1993
Phase I dose-escalation trial of iodine 131-labeled monoclonal antibody OKB7 in patients with non-Hodgkin's lymphomaM S Czuczman, D J Straus, C R Divgi, et al.
Cancer Treatment Reports|April 1, 1982
Multidisciplinary treatment of advanced Hodgkin's disease by an alternating chemotherapeutic regimen of MOPP/ABDV and low-dose radiation therapy restricted to originally bulky diseaseC W Young, D J Straus, J Myers, et al.
British Journal of Haematology|August 24, 2005
Primary mediastinal large B-cell lymphoma: optimal therapy and prognostic factor analysis in 141 consecutive patients treated at Memorial Sloan Kettering from 1980 to 1999Paul A Hamlin, Carol S Portlock, David J Straus, et al.
Cancer|July 15, 1980
The eight-drug/radiation therapy program (MOPP/ABDV/RT) for advanced Hodgkin's disease: a follow-up reportD J Straus, J Myers, S Passe, et al.
Pageof 22

Showing results (161-170 of 215) with videos related to

Sort By:
Pageof 22
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 1993
Accelerated hyperfractionated total-lymphoid irradiation, high-dose chemotherapy, and autologous bone marrow transplantation for refractory and relapsing patients with Hodgkin's diseaseJ Yahalom, S C Gulati, M Toia, et al.
Cancer|December 1, 1981
Angioimmunoblastic lymphadenopathy: clinical spectrum of diseaseP K Schauer, D J Straus, C M Bagley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1990
A phase I toxicity, pharmacology, and dosimetry trial of monoclonal antibody OKB7 in patients with non-Hodgkin's lymphoma: effects of tumor burden and antigen expressionD A Scheinberg, D J Straus, S D Yeh, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 18, 2007
Maintaining the dose intensity of ICE chemotherapy with a thrombopoietic agent, PEG-rHuMGDF, may confer a survival advantage in relapsed and refractory aggressive non-Hodgkin lymphomaC H Moskowitz, P A Hamlin, J Gabrilove, et al.
Cell Reports|September 9, 2023
The heat shock protein Hsp27 controls mitochondrial function by modulating ceramide generationRowan A Boyd, Saurav Majumder, Johnny Stiban, et al.
Leukemia & Lymphoma|September 7, 2000
Granulocyte-colony stimulating factor (G-CSF) may improve disease outcome in elderly patients with diffuse large cell lymphoma (DLCL) treated with CHOP chemotherapyG B Donnelly, J Glassman, C Long, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1993
Phase I dose-escalation trial of iodine 131-labeled monoclonal antibody OKB7 in patients with non-Hodgkin's lymphomaM S Czuczman, D J Straus, C R Divgi, et al.
Cancer Treatment Reports|April 1, 1982
Multidisciplinary treatment of advanced Hodgkin's disease by an alternating chemotherapeutic regimen of MOPP/ABDV and low-dose radiation therapy restricted to originally bulky diseaseC W Young, D J Straus, J Myers, et al.
British Journal of Haematology|August 24, 2005
Primary mediastinal large B-cell lymphoma: optimal therapy and prognostic factor analysis in 141 consecutive patients treated at Memorial Sloan Kettering from 1980 to 1999Paul A Hamlin, Carol S Portlock, David J Straus, et al.
Cancer|July 15, 1980
The eight-drug/radiation therapy program (MOPP/ABDV/RT) for advanced Hodgkin's disease: a follow-up reportD J Straus, J Myers, S Passe, et al.
Pageof 22